Literature DB >> 9479540

An adjuvant afterloading brachytherapy device for use after orbital exenteration in patients with orbital malignancies.

A Bacskulin1, M Ehrhardt, M Strietzel, H W Pau, H von Schwanewede, R Guthoff.   

Abstract

In cases of malignant diseases situated within the orbit and threaten to extend beyond it, removal of the orbit and periorbital contents may be indicated, followed by adjuvant chemotherapy or irradiation. An effective radiotherapy device for treatment of residual or suspicious cancer in the enucleated orbit consists of an external-beam radiation source (60Co) and an intraoperatively fitted mould as a guide for the flexible afterloading tubes using a 192Ir source. Considering the physical dose distribution and the local situation, this therapy permits a high dose with homogeneous dose distribution to the target area of the orbit but also allows significant dose reduction to adjunctive critical structures. Four patients with different orbital malignancies were treated by means of a combination of percutaneous radiotherapy with afterloading brachytherapy following orbital exenteration. The individual mould of the orbital cavity is modeled at the end of the operation. The technique of radiotherapy, dose distribution, and follow-up of the disease are demonstrated. Orbital malignancies with an extremely poor prognosis may profit from the application of this combined radiotherapy to avoid supraradical surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9479540

Source DB:  PubMed          Journal:  Ger J Ophthalmol        ISSN: 0941-2921


  2 in total

1.  Perioperative intensity-modulated brachytherapy for refractory orbital rhabdomyosarcomas in children.

Authors:  Rainer Joachim Strege; György Kovács; Jens Eduard Meyer; Detlef Holland; Alexander Claviez; Maximilian H Mehdorn
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

2.  Iodine-125 interstitial brachytherapy for malignant lacrimal sac tumours: an innovative technique.

Authors:  Ping Wang; Nan Ma; Shaobo Zhang; Xiaona Ning; Chenjun Guo; Qiong Zhang; Qilin Cheng; Yangjun Li
Journal:  Eye (Lond)       Date:  2020-07-16       Impact factor: 3.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.